Credit Suisse AG boosted its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 33.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,458 shares of the biotechnology company’s stock after buying an additional 11,516 shares during the period. Credit Suisse AG owned 0.24% of Enanta Pharmaceuticals worth $1,431,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. State Board of Administration of Florida Retirement System purchased a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth $204,000. Dimensional Fund Advisors LP raised its position in shares of Enanta Pharmaceuticals by 558.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 179,824 shares of the biotechnology company’s stock worth $6,024,000 after buying an additional 152,511 shares during the period. Guggenheim Capital LLC purchased a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth $1,024,000. Teachers Advisors LLC raised its position in shares of Enanta Pharmaceuticals by 3.3% in the fourth quarter. Teachers Advisors LLC now owns 24,482 shares of the biotechnology company’s stock worth $820,000 after buying an additional 777 shares during the period. Finally, Candriam Luxembourg S.C.A. raised its position in shares of Enanta Pharmaceuticals by 50.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 356,000 shares of the biotechnology company’s stock worth $10,965,000 after buying an additional 120,000 shares during the period. Institutional investors own 65.85% of the company’s stock.
Enanta Pharmaceuticals, Inc. (ENTA) traded up 0.63% during trading on Wednesday, reaching $39.88. The company’s stock had a trading volume of 12,324 shares. The company’s market cap is $760.91 million. Enanta Pharmaceuticals, Inc. has a 12 month low of $21.52 and a 12 month high of $41.20. The stock’s 50 day moving average is $37.54 and its 200 day moving average is $32.62.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The business had revenue of $7.51 million for the quarter, compared to analysts’ expectations of $8.08 million. During the same quarter in the previous year, the firm posted ($0.06) EPS. The business’s revenue for the quarter was down 46.3% compared to the same quarter last year. On average, equities analysts expect that Enanta Pharmaceuticals, Inc. will post $0.90 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/08/16/credit-suisse-ag-purchases-11516-shares-of-enanta-pharmaceuticals-inc-enta.html.
ENTA has been the topic of a number of recent research reports. Zacks Investment Research lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 12th. ValuEngine upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. JMP Securities upgraded Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price on the stock in a research note on Tuesday, July 11th. BidaskClub lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, Robert W. Baird increased their target price on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 8th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Enanta Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $36.00.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
What are top analysts saying about Enanta Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enanta Pharmaceuticals Inc. and related companies.